Treeline Biosciences announced it raised $422 Million in an initial filing from an offering of $422 Million

Company

Location

About

Treeline (or Treeline Biosciences) is a privately held, clinical-stage biopharma company that aspires to make medicines at the highest level. We match compelling disease targets with proven drug approaches, by integrating in-house R&D with leading-edge computational tools. We choose programs with the potential to redefine the treatment of cancer and other serious diseases. We are led by a team of biology, chemistry, protein science, computation, and clinical development leaders working across the U.S. and Europe.